NeuroPace (NPCE) Cash from Financing Activities (2020 - 2026)
NeuroPace (NPCE) posted Cash from Financing Activities of $1.2 million for Q2 2026, up 808.43% on a QoQ basis from -$166000.0 in Q1 2026, and up 161.64% year-over-year from $449480.8 in Q2 2025.
Powered by 
Analysis
NeuroPace (NPCE) Cash from Financing Activities (2020 - 2026) Analysis & Trends
NeuroPace has reported Cash from Financing Activities for 7 years, with the latest figure at $1.2 million in Q2 2026.
- On a quarterly basis, Cash from Financing Activities rose 161.64% year-over-year to $1.2 million in Q2 2026; TTM through Jun 2026 was $1.4 million, a 93.86% decrease from a year earlier, with the FY2025 full-year figure at $19.6 million, up 352.97% from the prior year.
- Cash from Financing Activities was $1.2 million for Q2 2026 at NeuroPace, up from -$166000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $21.1 million in Q1 2025, with the low at -$1.9 million in Q2 2025.
- Average Cash from Financing Activities over 5 years is $1.9 million, with a median of $133500.0 recorded in 2023.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities slumped 25600.0% in 2023, then surged 29216.67% in 2025.
- Over 5 years, Cash from Financing Activities stood at -$138000.0 in 2022, then soared by 6052.17% to $8.2 million in 2023, then tumbled by 89.68% to $848000.0 in 2024, then dropped by 25.12% to $635000.0 in 2025, then jumped by 85.2% to $1.2 million in 2026.
- The last three Cash from Financing Activities figures came in at $1.2 million (Q2 2026), -$166000.0 (Q1 2026), and $635000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | -287.90 Mn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | -343.00 Mn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | -95.00 Mn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | -410.00 Mn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | -300,000.00 |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | -510.00 Mn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | -607.30 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | -213.50 Mn |
| 10 | NeuroPace | 493.15 Mn | 441.45 Mn | 18.91 Mn | 1.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.18 Mn |
| Mar 31, 2026 | -166,000.00 |
| Dec 31, 2025 | 635,000.00 |
| Sep 30, 2025 | -235,000.00 |
| Jun 30, 2025 | -1.91 Mn |
| Mar 31, 2025 | 21.11 Mn |
| Dec 31, 2024 | 848,000.00 |
| Sep 30, 2024 | 2.90 Mn |
| Jun 30, 2024 | 509,000.00 |
| Mar 31, 2024 | 72,000.00 |
| Dec 31, 2023 | 8.21 Mn |
| Sep 30, 2023 | -27,000.00 |
| Jun 30, 2023 | 195,000.00 |
| Mar 31, 2023 | -255,000.00 |
| Dec 31, 2022 | -138,000.00 |
| Sep 30, 2022 | -8,000.00 |
| Jun 30, 2022 | 635,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Dec 31, 2021 | 911,000.00 |
| Jun 30, 2021 | 103.19 Mn |